Quick Answer
PAVmed Inc. reported Total Revenue of $71.0 thousand for fiscal year 2025.
PAVmed Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $71.0K -97.6% |
$3.00M +22.1% |
$2.45M +550.4% |
$377.0K -24.6% |
$500.0K | — |
| Revenue (ASC 606) | $71.0K -97.6% |
$3.00M +22.1% |
$2.45M +550.4% |
$377.0K -24.6% |
$500.0K | — |
| Net Income | $401.0K -99.0% |
$39.79M +162.0% |
-$64.17M +27.9% |
-$88.98M -76.7% |
-$50.35M -46.9% |
-$34.28M -108.3% |
| Diluted EPS | -$5.63 -137.8% |
$14.90 +262.7% |
-$9.16 +39.1% |
-$15.03 | — | — |
| Total Assets | $38.81M +26.6% |
$30.66M -7.4% |
$33.12M -38.6% |
$53.98M -37.9% |
$86.98M +339.8% |
$19.78M +173.2% |
| Cash and Equivalents | $1.54M +29.8% |
$1.19M -94.0% |
$19.64M -50.6% |
$39.74M -48.6% |
$77.26M +347.7% |
$17.26M +177.5% |
| Stockholders Equity | $33.97M +1461.4% |
-$2.50M +95.4% |
-$53.83M -456.0% |
-$9.68M -115.7% |
$61.67M +3152.4% |
$1.90M +149.6% |
| R&D Expense | $4.49M -24.3% |
$5.93M -58.4% |
$14.28M -43.7% |
$25.34M +27.7% |
$19.85M +81.0% |
$10.96M +65.4% |
| Operating Income | -$21.81M +51.0% |
-$44.49M +35.3% |
-$68.80M +24.5% |
-$91.09M -67.5% |
-$54.39M -132.9% |
-$23.35M -63.4% |
| Gross Profit | — | — | — | — | -$85.0K | — |
| Shares Outstanding | 927,934 +148.6% |
373,300 -95.6% |
8.58M +36.2% |
6.30M -92.7% |
86.37M +35.3% |
63.82M +57.7% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $5.0K | -99.5% | -16.7% |
| Revenue (ASC 606) | September 30, 2025 | $5.0K | -99.5% | -16.7% |
| Net Income | September 30, 2025 | -$5.38M | -108.4% | +54.8% |
| Diluted EPS | September 30, 2025 | -$0.29 | -120.1% | +60.8% |
| Total Assets | September 30, 2025 | $38.07M | +24.6% | -13.3% |
| Cash and Equivalents | September 30, 2024 | $765.0K | -97.1% | -97.0% |
| Stockholders Equity | September 30, 2025 | $32.52M | +767.9% | -13.3% |
| R&D Expense | September 30, 2025 | $1.09M | -29.4% | +37.7% |
| Operating Income | September 30, 2025 | -$4.84M | +58.2% | -2.7% |
| Gross Profit | March 31, 2022 | -$180.0K | — | -421.4% |
| Shares Outstanding | September 30, 2025 | 23.05M | +116.3% | +14.5% |
- PAVmed Inc. reported Total Revenue of $71.0 thousand for fiscal year 2025.
- PAVmed Inc. showed a decrease of -97.6% in Total Revenue compared to the prior fiscal year.
- PAVmed Inc. reported Revenue (ASC 606) of $71.0 thousand for fiscal year 2025.
- PAVmed Inc. showed a decrease of -97.6% in Revenue (ASC 606) compared to the prior fiscal year.
- PAVmed Inc. reported Net Income of $401.0 thousand for fiscal year 2025.
- PAVmed Inc. showed a decrease of -99.0% in Net Income compared to the prior fiscal year.
- PAVmed Inc. reported Diluted EPS of $5.63 per share (loss) for fiscal year 2025.
- PAVmed Inc. showed a decrease of -137.8% in Diluted EPS compared to the prior fiscal year.
- PAVmed Inc. reported Total Assets of $38.81 million for fiscal year 2025.
- PAVmed Inc. showed an increase of +26.6% in Total Assets compared to the prior fiscal year.
- PAVmed Inc. reported Cash and Equivalents of $1.54 million for fiscal year 2025.
- PAVmed Inc. showed an increase of +29.8% in Cash and Equivalents compared to the prior fiscal year.
- PAVmed Inc. reported Stockholders Equity of $33.97 million for fiscal year 2025.
- PAVmed Inc. showed an increase of +1461.4% in Stockholders Equity compared to the prior fiscal year.
- PAVmed Inc. reported R&D Expense of $4.49 million for fiscal year 2025.
- PAVmed Inc. showed a decrease of -24.3% in R&D Expense compared to the prior fiscal year.
- PAVmed Inc. reported Operating Income of -$21.81 million for fiscal year 2025.
- PAVmed Inc. showed an increase of +51.0% in Operating Income compared to the prior fiscal year.
- PAVmed Inc. reported Gross Profit of -$85.0 thousand for fiscal year 2021.
- PAVmed Inc. reported Shares Outstanding of 927.9 thousand shares for fiscal year 2025.
- PAVmed Inc. showed an increase of +148.6% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: